Edition:
United States

Zosano Pharma Corp (ZSAN.OQ)

ZSAN.OQ on NASDAQ Stock Exchange Capital Market

4.43USD
20 Feb 2018
Change (% chg)

$0.08 (+1.72%)
Prev Close
$4.36
Open
$4.25
Day's High
$4.61
Day's Low
$4.25
Volume
5,731
Avg. Vol
12,052
52-wk High
$63.40
52-wk Low
$3.63

Chart for

About

Zosano Pharma Corporation is a clinical-stage specialty pharmaceutical company. The Company has developed a transdermal microneedle patch system to deliver its formulations of existing drugs through the skin for the treatment of a range of indications. Its microneedle patch system offers consistent drug delivery and improved... (more)

Overall

Beta: --
Market Cap(Mil.): $8.47
Shares Outstanding(Mil.): 1.97
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 180.40 17.28
EPS (TTM): -- -- --
ROI: -- -0.52 35.61
ROE: -- -3.30 17.17

BRIEF-Zosano Pharma Files Prospectus Related Offering 12.5 Mln Shares

* ZOSANO PHARMA CORP FILES PROSPECTUS RELATED OFFERING 12.5 MILLION SHARES OF CO'S COMMON STOCK - SEC FILING Source text: (http://bit.ly/2EDTBag) Further company coverage:

Feb 13 2018

BRIEF-Zosano Pharma Files Prospectus Related To 10 Mln Stock Offering

* ZOSANO PHARMA CORP FILES PROSPECTUS RELATED TO OFFERING 10 MILLION SHARES OF CO'S COMMON STOCK - SEC FILING‍​ Source text (http://bit.ly/2GUOzEr) Further company coverage:

Feb 06 2018

BRIEF-Zosano Pharma Files For Offering Of Up To $57.5 Million Shares

* ZOSANO PHARMA FILES FOR OFFERING OF UP TO $57.5 MILLION SHARES - SEC FILING Source text :[http://bit.ly/2BPJFqj] Further company coverage:

Dec 22 2017

BRIEF-Zosano Pharma Says Board To Reduce Size To Five

* ZOSANO PHARMA SAYS BOARD OF DIRECTORS ADOPTED A RESOLUTION TO REDUCE SIZE OF BOARD TO FIVE DIRECTORS - SEC FILING Source: (http://bit.ly/2j7YwDM) Further company coverage:

Dec 15 2017

BRIEF-Zosano pharma Q3 loss per share $0.20

* Zosano pharma reports third quarter 2017 financial results and operational update

Nov 09 2017

BRIEF-Zosano Pharma announces initiation of long-term safety study for M207

* Zosano Pharma announces initiation of long-term safety study for M207 as an acute treatment of migraine Source text for Eikon: Further company coverage:

Nov 08 2017

BRIEF-Zosano enters into common stock purchase agreement with Lincoln Park Capital

* Zosano enters into common stock purchase agreement with Lincoln Park Capital Source text for Eikon: Further company coverage:

Oct 20 2017

BRIEF-Zosano appoints Kenneth Greathouse to board of directors

* Zosano appoints Kenneth Greathouse to board of directors Source text for Eikon: Further company coverage:

Oct 04 2017

BRIEF-Zosano provides patent application update

* Zosano Pharma Corp - Received official written notification of an office action from U.S. patent and trademark office

Sep 26 2017

Earnings vs. Estimates